Related Experiment Videos
Is it Time to Fold the Cysts Away?
Matteus Krappitz1, Anna-Rachel Gallagher1, Sorin Fedeles1
1Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
Trends in Molecular Medicine
|October 30, 2016
Summary
Optimizing protein folding for polycystic kidney disease (PKD) gene mutations may slow disease progression in animal models. This approach could offer new therapeutic strategies for specific patient groups with autosomal dominant polycystic kidney disease (ADPKD).
Area of Science:
- Genetics and Molecular Biology
- Nephrology
- Biochemistry
Background:
- Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by kidney cyst formation.
- Mutations in the PKD1 and PKD2 genes, encoding polycystin-1 and polycystin-2, are the primary cause of ADPKD.
- Understanding the molecular mechanisms underlying polycystin dysfunction is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the potential therapeutic impact of optimizing the cellular folding environment for polycystin-1.
- To evaluate whether modulating protein folding can influence the progression of ADPKD in preclinical models.
- To explore novel therapeutic avenues for specific subgroups of ADPKD patients based on genetic mutations.
Main Methods:
- Utilized animal models of ADPKD with specific polycystin-1 missense mutations.
- Employed techniques to optimize the protein folding environment within affected cells.
- Assessed the effects of optimized folding on cystogenesis and disease progression markers.
Main Results:
- Modifying the folding environment for polycystin-1 demonstrated a significant impact on ADPKD progression in animal models.
- Evidence suggests that proper protein folding is critical for mitigating the effects of certain PKD1 mutations.
- These findings highlight the potential of chaperone-based or other folding-optimization strategies.
Conclusions:
- Optimizing the folding environment for polycystin-1 presents a promising therapeutic strategy for ADPKD.
- This approach may offer targeted treatment options for patients with specific polycystin-1 missense mutations.
- Further research into protein folding modulation could unlock new therapeutic avenues for genetic kidney diseases.